Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  NEOVACS    ALNEV   FR0004032746

NEOVACS

(ALNEV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Euronext Growth Paris
11/27/2020 11/30/2020 12/01/2020 12/02/2020 Date
0.0346(c) 0.0335(c) 0.0324(c) 0.0313(c) 0.0322 Last
43 392 390 29 342 086 29 125 779 14 309 385 9 118 730 Volume
-7.49% -3.18% -3.28% -3.40% +2.88% Change
More quotes
Financials
Sales 2017 0,81 M 0,99 M 0,99 M
Net income 2017 -14,8 M -18,1 M -18,1 M
Net cash position 2017 2,70 M 3,28 M 3,28 M
P/E ratio 2017 -2,19x
Yield 2017 -
Sales 2018 0,11 M 0,14 M 0,14 M
Net income 2018 -10,8 M -13,1 M -13,1 M
Net cash position 2018 1,35 M 1,65 M 1,65 M
P/E ratio 2018 -2,03x
Yield 2018 -
Capitalization 5,64 M 6,81 M 6,86 M
EV / Sales 2017 31,5x
EV / Sales 2018 171x
Nbr of Employees 24
Free-Float 98,1%
More Financials
Company
Néovacs has become a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. With its innovative technology inducing a polyclonal immune response, protected by four patent families potentially until 2032, Néovacs focuses its clinical efforts on the development of IFNa-Kinoid for treating lupus and dermatomyositis. The group also carries out preclinical work on other... 
More about the company
All news about NEOVACS
10/31NEOVACS : Monthly statement on outstanding equity shares and voting rights
CO
08/18NEOVACS : Tableau de suivi des VM donnant accès au capital (OCEANEs) au 11/08/20..
PU
05/19NEOVACS : Neovacs shares to resume trading on may 20th, 2020
AN
05/18NEOVACS : Validation of the "restarted" plan by the paris commercial court
AN
05/04NEOVACS : DRAFT CONTINUITY PLAN // REVIEW HEARING SCHEDULED FOR MAY 6th, 2020
AN
03/09NEOVACS : EXTENSION OF THE OBSERVATION PERIOD IN THE FRAME OF REOGANIZATION PROC..
AN
2019NEOVACS : Requests a reorganization proceedings of the company
GL
2019NEOVACS : Half-year results
CO
2019NEOVACS : Announces appointment of vincent serra as chief...
PU
2019NEOVACS : Regulated Information August 31st 2019
PU
2019AstraZeneca lupus drug shows promise after set-back last year
RE
2019NEOVACS : Half year report on the liquidity contract as of june 30, 2019
PU
2019NEOVACS : Announces that the positive results of its proof of concept in allergi..
GL
2019NEOVACS : Regulated information April 30, 2019
PU
2019NEOVACS : Regulated information May 31, 2019
PU
More news
News in other languages on NEOVACS
12/02NEOVACS : Tableau de suivi des VM donnant accès au capital (ORNANEs) au 02 décem..
12/02NEOVACS : Tableau de suivi des VM donnant accès au capital (OCEANES) au 02 décem..
12/02NEOVACS : Tableau de suivi des VM donnant accès au capital (BSA) au 02 décembre ..
12/02NEOVACS : Tableau de suivi des actions en circulation (SYNTHESE) au 02 décembre ..
11/30NEOVACS : Tableau de suivi des VM donnant accès au capital (ORNANEs) au 30 novem..
More news
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR0004032746 | MarketScreener
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers
NameTitle
Vincent Serra Chief Executive Officer
Baptiste Pourtout Chief Financial Officer
Thérèse Croughs Chief Medical Officer
Daniel Zagury Director
Jean-Jacques Bertrand Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS-46.03%7
MODERNA, INC.631.08%56 587
LONZA GROUP AG56.34%45 782
CELLTRION, INC.91.71%42 101
IQVIA HOLDINGS INC.10.05%32 601
SEAGEN INC.54.94%31 921